Search clinical trials for: GSK962040

Total 10 results

GlaxoSmithKline

Completed

The Effect of Single Doses of the Motilin Receptor Agonist GSK962040 in Type I Diabetic Patients With Gastroparesis

Gastroparesis

Belgium, Sweden
GlaxoSmithKline

Completed

Dose Response of 28 Days of Dosing of GSK962040 in Type I and II Diabetic Male and Female Subjects With Gastroparesis

Gastroparesis

United States, Australia, Belgium, United Kingdom, Canada, Sweden
GlaxoSmithKline

Completed

Evaluation of Single Doses of GSK962040 in Critically Ill Patients With Enteral Feed Intolerance

Gastroparesis

Australia
GlaxoSmithKline

Completed

A Study to Evaluate Safety, Side Effects, Muscle Activity and Speed of Gastric Emptying of GSK962040

Gastroparesis

Belgium
GlaxoSmithKline

Completed

Evaluation of the Safety, Tolerability and Pharmacokinetics of Repeat Oral Doses of GSK962040 Administered to Healthy Adult Subjects.

Gastroparesis

United Kingdom
GlaxoSmithKline

Completed

A Study to Assess the Effect of Repeat Doses of GSK962040 on the Pharmacokinetics of L-DOPA in Subjects With Parkinson's Disease Exhibiting Delayed Gastric Emptying

Gastroparesis

Germany, Australia, Sweden, United Kingdom
RemeGen Co., Ltd.

Completed

Evaluation of RC28-E Injection in Wet Age-related Macular Degeneration

Wet Age-Related Macular Degeneration

China
Kafrelsheikh University

Unknown

Efficacy of Sunlight Activated Synthetic Porphyrin in COVID-19 Infected Patients (SnPPIX)

COVID-19

Egypt
GlaxoSmithKline

Terminated

Nutritional Adequacy Therapeutic Enhancement in the Critically Ill. The NUTRIATE Study

Gastroparesis

Canada, Australia, United States
GlaxoSmithKline

Completed

GSK962040 Drug-drug Interaction Study With Ketoconazole

Gastroparesis

United States

3

Subscribe